Gastroenterology: Prognosis for patients with liver fibrosis and non-alcoholic fatty liver disease

Biopsy confirmed liver fibrosis is an important factor in the prognosis of non-alcoholic fatty liver disease (NAFLD) patients, and researchers recently conducted a systematic review and meta-analysis to quantify the prognostic value of the fibrosis phase of non-alcoholic fatty hepatitis (NASH) patients in NAFLD patientsresearchers collected data as of August 2018 on clinical outcomes in adult NAFLD or NASH patients, including deaths (all causes and liver-related) and disease (cirrhosis, liver cancer and liver-related events) in patients with different stages of fibrosis13 studies, including a total of 4,428 NAFLD and 2,875 NASH patientsCompared with patients with no fibrosis (stage 0), the risk of total death of stage 4 fibrosis was 3.42, liver-related death risk was 11.13, liver transplant risk was 5.42, liver event risk was 12.78, and the effect of age and sex on the risk was not significantstudy found that biopsy-confirmed liver fibrosis led to a significant increase in the risk of death and adverse prognosis in patients with non-alcoholic fatty liver disease